ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

ClinicalTrials.gov ID: NCT02186873

Public ClinicalTrials.gov record NCT02186873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis

Study identification

NCT ID
NCT02186873
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
208 participants

Conditions and interventions

Interventions

  • Golimumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2, 2014
Primary completion
Dec 14, 2015
Completion
Oct 10, 2016
Last update posted
Oct 29, 2025

2014 – 2016

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Not listed Glendale Arizona
Not listed Mesa Arizona
Not listed La Palma California
Not listed Granger Indiana
Not listed St Louis Missouri
Not listed Orchard Park New York
Not listed Salisbury North Carolina
Not listed Middleburg Heights Ohio
Not listed Duncansville Pennsylvania
Not listed Austin Texas
Not listed Houston Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02186873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 29, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02186873 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →